Spots Global Cancer Trial Database for derazantinib 300 mg once daily monotherapy (qd)
Every month we try and update this database with for derazantinib 300 mg once daily monotherapy (qd) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Derazantinib and Atezolizumab in Patients With Urothelial Cancer | NCT04045613 | Urothelial Carc... | Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20... | 18 Years - | Basilea Pharmaceutica | |
Derazantinib and Atezolizumab in Patients With Urothelial Cancer | NCT04045613 | Urothelial Carc... | Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20... | 18 Years - | Basilea Pharmaceutica |